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One of the most important factors inﬂuencing embryo viability is chromosome imbalance (aneuploidy). Embryos derived from
aneuploid gametes have little potential for forming a viable pregnancy, but cannot be distinguished from normal embryos
using standard morphological evaluation. For more than a decade, preimplantation genetic screening (PGS) has been used to
assist in the identiﬁcation of aneuploid embryos. However, current strategies, based upon cell biopsy followed by ﬂuorescent in
situ hybridization, allow less than half of the chromosomes to be screened. In this review, we discuss methods that overcome
the limitations of earlier PGS strategies and provide screening of the entire chromosome complement in oocytes and embryos.
In recent months, there has been a rapid growth in the number of PGS cycles utilizing one such method, comparative genomic
hybridization (CGH). Data from IVF cycles utilizing CGH must be considered preliminary, but appear to indicate a dramatic
increase in embryo implantation following comprehensive chromosomal screening. It is expected that methods based upon micro-
arrays will yield similar clinical results and may be sufﬁciently rapid to permit comprehensive screening without the need for
embryo cryopreservation. Some microarray platforms also offer the advantage of embryo ﬁngerprinting and the potential for
combined aneuploidy and single gene disorder diagnosis. However, more data concerning accuracy and further reductions in
the price of tests will be necessary before microarrays can be widely applied.
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The need for embryo viability assessment
The use of controlled ovarian stimulation in assisted reproductive
treatment (ART) cycles generally results in the production of multiple
mature oocytes. Fertilization rates are usually high and consequently it
is typical for several embryos to be produced each treatment cycle. In
order to maximize the probability of obtaining a pregnancy, most IVF
cycles involve the transfer of more than one embryo. Although this
approach increases the likelihood of obtaining a pregnancy, it also
leads to an elevated risk of multiple gestation (twins, triplets, etc).
Multiple pregnancies are associated with signiﬁcantly elevated risks
of serious complications for both the mother and the children. For
example, mothers have an increased incidence of pre-eclampsia, post-
partum hemorrhage, hysterectomy and gestational diabetes (Walker
et al., 2004), whereas infants are at greater risk of low birthweight,
preterm delivery, cerebral palsy and congenital malformations
(Bergh et al., 1999; Stromberg et al., 2002; Pinborg et al., 2003).
Concern over the high incidence of multiple pregnancies in ART
cycles has led to increasing pressure on physicians to restrict the
number of embryos transferred to the uterus.
Not surprisingly, decreasing the number of embryos transferred to
the uterus is extremely effective at reducing multiple pregnancy
rates (Gerris, 2007; Sunde, 2007). However, the transfer of fewer
embryos is also likely to have an adverse impact on ART pregnancy
rates. The problem stems from the fact that there is great heterogeneity
in the viability of individual human embryos generated in vitro.I n
order to maintain satisfactory pregnancy rates, while reducing the
number of embryos transferred, it is essential to identify the
embryos having the greatest potential for pregnancy formation and
insure that these embryos are given priority for transfer. The most
common strategy for the identiﬁcation of viable embryos is based
upon assessment of morphological criteria, such as cell size and
number, presence of multinucleation, percentage of fragmentation
and cleavage rate (Cummins et al., 1986; Puissant et al., 1987;
Van Royen et al., 1999; reviewed in Sakkas and Gardner, 2005).
Morphological evaluation is utilized in all IVF laboratories and
remains the mainstay of embryo assessment. However, some of the
most important aspects of embryo viability remain invisible to such
analyses.
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Many morphologically normal embryos do not achieve implantation or
spontaneously abort during pregnancy. In most cases, the underlying
basis of this failure remains unknown. However, it is likely that many
unsuccessful IVF attempts can be explained by the presence of numeri-
cal chromosomal abnormalities (aneuploidy). The high prevalence of
aneuploidy in human oocytes and embryos has long been recognized
(Angell etal.,1983; Veiga etal.,1987; Delhanty etal.,1993;Kamiguchi
et al., 1993; Munne ´ et al., 1993) and the developmental impact
of these anomalies, at least those of meiotic origin, is well documen-
ted. Early data from Hassold and others demonstrated that at least
50% of ﬁrst trimester spontaneous miscarriages are chromosomally
abnormal (Hassold and Jacobs, 1984), whereas more recent studies
employing molecular cytogenetic techniques suggest the true inci-
dence of aneuploidy may be even higher, perhaps exceeding
65% (Menasha et al., 2005). Data from prenatal samples and
spontaneous miscarriages have indicated a dramatic increase in chro-
mosomally abnormal pregnancies with advancing maternal age. These
data are mirrored by ﬁndings from the direct cytogenetic analysis of
human oocytes, which demonstrates oocyte aneuploidy rates in
excess of 50% for many women over 40 years of age (Sandalinas
et al.,2002; Kuliev et al., 2003; Pellestor etal., 2003;Gutie ´rrez-Mateo
et al., 2004; Fragouli et al., 2006; Hassold et al., 2007; Sher et al.,
2007).
Given that chromosome imbalance of meiotic origin is common,
and almost always lethal to the embryo or fetus, it has been suggested
that screening oocytes or embryos for chromosome abnormalities
could greatly assist the identiﬁcation of the most viable embryos.
Such an approach is expected to be particularly beneﬁcial for patients
predisposed to the production of large numbers of aneuploid gametes,
such as those of advanced maternal age (AMA). Theoretically, aneu-
ploidy screening and preferential transfer of euploid embryos should
lead to improved pregnancy rate, decreased miscarriage rate and
reduced risk of aneuploid syndromes, such as Down, Edwards,
Patau, Klinefelter and Turner (Munne ´ et al., 1993).
Inrecentyears,severalgroupshaveinitiatedresearchaimedatidentify-
ing non-invasive markers of chromosome imbalance. Some investigators
have detected characteristic transcriptional changes in the cumulus cells
attached to aneuploid oocytes (Fragouli et al., 2007), whereas others
have identiﬁed alterations in the molecules secreted by aneuploid
embryos (i.e. the secretome) (Katz-Jaffe et al., 2006). Another study
discovered several genes, producing cell surface or secretory proteins,
which display aberrant expression in chromosomally abnormal oocytes
(Wellsetal.,2006).Althoughthesestudieshaverevealedsomepromising
marker genes and proteins, further validation is necessary, and a widely
available clinical test still seems some way off.
Currently, the only reliable methods for aneuploidy detection
require biopsy of material from the oocyte or embryo. Information
concerning the chromosomes of oocytes can be obtained by analysis
of the associated polar bodies (Kuliev and Verlinsky, 2005), while
embryos can be assessed by testing single blastomeres biopsied at
the cleavage stage (Day 3 post-fertilization) (Gianaroli et al., 1997;
Munne ´ et al., 1999) or by analysis of several cells removed from
the trophectoderm at the blastocyst stage (Day 5 post-fertilization)
(McArthur et al., 2005, 2008).
The application of conventional techniques of chromosome prep-
aration (karyotyping) to human preimplantation embryos has proven
to be difﬁcult and unsatisfactory. In most cases, only one cell is avail-
able for analysis, greatly reducing the likelihood of obtaining the high-
quality metaphase chromosomes essential for chromosome banding
studies. Indeed, biopsied blastomeres are almost always in interphase,
with the chromosomes contained within the nucleus rather than
visible as distinct entities. On the rare occasions when blastomeres in
metaphase are obtained, the chromosomes tend to be highly contracted,
a morphology unsuitable for traditional karyotyping methods. Mor-
phology is similarly poor for chromosomes derived from polar
bodies. For these reasons, molecular cytogenetic techniques, especially
ﬂuorescence in situ hybridization (FISH), have become the methods of
choice for the analysis of chromosomes from embryos (Munne ´ et al.,
1993, 1997; Delhanty et al., 1993; Gianaroli et al., 1997).
The use of FISH for screening oocytes and embryos
FISH with chromosome-speciﬁc DNA probes can be applied to single
cells and gives detectable signals in interphase nuclei as well as on
metaphase chromosomes. The ﬁrst application of this technology to
human blastomeres was demonstrated by Grifﬁn et al. (1992). Since
that time, thousands of IVF patients have had their embryos screened
for aneuploidy using FISH, a process variously termed preimplanta-
tion genetic screening (PGS), preimplantation genetic diagnosis for
aneuploidy screening (PGD-AS) or PGD for infertility. Most of
these patients are considered to be at elevated risk of producing aneu-
ploid embryos due to AMA, repeated implantation failure or recurrent
miscarriages. Several groups have reported a decrease in spontaneous
miscarriages (Munne ´ et al., 2005; Schoolcraft et al., 2008a) and/or an
increase in the implantation and live birth rates per embryo transfer
following these procedures (Munne ´ et al., 1999, 2003, 2005; Gianaroli
et al., 1999).
Although several FISH studies have yielded positive clinical data,
other reports have suggested that PGS using this method does not
lead to improved IVF outcomes, at least in terms of pregnancy/birth
rate per treatment cycle (Staessen et al., 2004; Mastenbroek et al.,
2007). Some of the disparities in the published data may be a conse-
quence of differences in patient selection, methodology or limitations
of the FISH technique itself (Munne ´ et al., 2007a,b). The number of
chromosomes screened and the choice of which chromosomes to
assess are both vital aspects of the method, yet show signiﬁcant vari-
ation between the studies. Additionally, it is essential that the accuracy
rate and the proportion of cells producing a diagnostic result are high,
which has not always been the case for published FISH studies
(Mastenbroek et al., 2007).
Although embryo screening using well-optimized FISH methods
may lead to improved outcomes for appropriately indicated patients,
it is acknowledged that this approach does have some technical limit-
ations. First, relatively few chromosomes can be assessed, as only a
limited number of spectrally distinct ﬂuorochromes (colors) are avail-
able for the labeling of DNA probes. To get around this limitation,
multiple rounds of FISH can be employed, analyzing one set of
probes then washing them off and recycling the same colors in
order to assess a different set of chromosomes. However, the accuracy
of the FISH analysis decreases with each additional round of hybrid-
ization and for this reason it is inadvisable to performmore than two or
three sequential rounds of FISH. The most comprehensive FISH
methods currently used for routine embryo screening assess approxi-
mately half of the chromosomes and it is therefore inevitable that
some abnormal embryos remain undetected. Another limitation of
the FISH procedure is that it is dependent on ﬁxation of a single
cell onto a microscope slide, a procedure that requires skill and experi-
ence. The spreading of a cell on a slide can lead to overlapping or split
signals, which are difﬁcult to score correctly, necessitating an
additional round of conﬁrmatory FISH analysis using an alternative
probe for the questionable chromosome, a process that has been
termed no result rescue (Colls et al., 2007).
Wells et al.
704Comparative genomic hybridization
In 1996, a molecular cytogenetic method allowing the simultaneous
enumeration of all of the chromosomes in a single cell was developed
and applied to blastomeres for the ﬁrst time (Wells and Delhanty,
1996). The method was based upon comparative genomic hybridiz-
ation (CGH), a technique originally developed for the evaluation of
chromosomal losses and gains in tumors (Kallioniemi et al., 1992).
CGH is a DNA-based method, which is applicable to cells in any
phase of the cell cycle and avoids ﬁxation and spreading. The tech-
nique employs a competitive hybridization of differentially labeled
DNA samples (DNA from the sample: green; chromosomally
normal reference DNA: red) to normal metaphase chromosomes on
a microscope slide. Fragments of the red (reference) and green
(sample) DNAs anneal to their complementary sequences on the
chromosomes, such that each chromosome becomes coated with thou-
sands of red and green DNA fragments (Fig. 1). The ratio of green:red
ﬂuorescence along the length of each chromosome reveals the relative
number of chromosome copies in the test sample compared with the
reference (Kallioniemi et al., 1992). An excess of green ﬂuorescence
on a speciﬁc chromosome is indicative of a chromosomal gain (e.g. a
trisomy), whereas an excess of red ﬂuorescence is indicative of
chromosome loss. The CGH method requires 1 mg of DNA
whereas a single cell contains only 5–10 pg, and for this reason it is
necessary to amplify the entire genome of cells prior to CGH analysis.
Although various methods can be employed for this purpose, the most
widely used is a technique based upon the annealing of semi-
degenerate primers followed by polymerase chain reaction (PCR)
mediated ampliﬁcation, known as degenerate oligonucleotide
primed (DOP) PCR (Telenius et al., 1992; Wells et al., 1999).
Studies applying CGH to the analysis of embryos provided fascinat-
ing data on the variety and frequency of chromosome abnormalities in
human embryos and conﬁrmed that aneuploidy canaffect any chromo-
some during human preimplantation development, including the
largest chromosomes. Some of the aneuploidies detected are of
types never observed in prenatal samples or material from spon-
taneous miscarriages and are presumed to cause developmental
arrest during the preimplantation phase, implantation failure or extre-
mely early miscarriage. CGH was also capable of detecting some
abnormalities not readily detectable using FISH, including chromo-
some breakage (Wells and Delhanty, 2000; Voullaire et al., 2000).
Analysis of the published CGH data reveals that 20–40% of
embryos carry chromosome abnormalities that would not be detect-
able using commercially available FISH screens used for PGS
(Wells and Delhanty, 2000; Voullaire et al., 2002; Wilton et al.,
2003). The fact that current aneuploidy screening protocols are not
100% successful at preventing the transfer of aneuploid embryos
potentially reduces their effectiveness as a method for embryo evalu-
ation. However, CGH has conﬁrmed that not all chromosomes have an
equal risk of aneuploidy. To date, FISH panels have tended to focus on
screening of the chromosomes most often aneuploid in prenatal
Figure 1: Clinical screening of a human blastocyst using CGH.
(A) Normal metaphase chromosomes hybridized with test and reference DNAs. The test DNA (green) was composed of ampliﬁed material derived from biopsied
trophectoderm cells. The reference DNA (red) was derived from a chromosomally normal male. (B) Ratio proﬁles for chromosomes 10, 19, 20 and 21, revealing
additional copies of chromosomes 10 and 19 and loss of chromosomes 20 and 21. The most likely karyotype for this embryo is 46,XY,þ10,þ19,220,221.
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705samples and miscarriages, but it is clear from CGH results that these
chromosomes are not necessarily the most important in terms of pre-
implantation aneuploidy. Recently, a new panel of FISH probes has
been introduced for embryo screening, based upon the 10 chromo-
somes most often shown to be aneuploid in embryos using CGH. It
is estimated that this strategy could allow the detection of over 85%
of aneuploid embryos (Reprogenetics, unpublished).
Although it is possible to achieve high detection rates for aneuploid
embryos without screening the entire chromosome complement, it is
inevitable that maximum accuracy will only be achieved when all
the chromosomes are evaluated. For this reason, the application of
CGH to the screening of oocytes and embryos is an attractive possi-
bility. The principal difﬁculties in using CGH clinically are the
length of time required for the method (4 days), which is incompa-
tible with the restricted timeframe available for preimplantation
testing, and the high complexity of the technique. One early attempt
at clinical application focused on the use of an accelerated CGH pro-
tocol applied to ﬁrst polar bodies biopsied on the day of fertilization
(Day 0). This strategy allowed results to be obtained by Day 3 post-
fertilization and was therefore compatible with a fresh embryo transfer
(Wells et al., 2002). However, aneuploidies arising in meiosis II, as
well as those of paternal origin, could not be detected using this
approach. More recently, pregnancies have been obtained after com-
prehensive chromosome screening of polar bodies using CGH, com-
bined with diagnosis of single gene disorders. For this purpose, the
ﬁrst polar body was biopsied and analyzed using CGH and a single
blastomere was biopsied on Day 3 and used for single gene testing
(Obradors et al., 2008).
An alternative approach to polar body analysis utilized Day 3 blas-
tomere biopsy coupled with cryopreservation (Wilton et al., 2001,
2003; Voullaire et al., 2002). In this case, embryos remained frozen
while CGH analysis was carried out, with those diagnosed normal
thawed and transferred in a subsequent cycle. This strategy was suc-
cessfully clinically applied, leading to multiple births for a variety
of infertile patients. The main drawback of this approach is that con-
ventional freezing and thawing methods lead to a reduction in embryo
implantation potential, a problem exacerbated by embryo biopsy.
Although initial results from clinical CGH studies showed promise,
relatively few cases were performed and interest in this approach
appeared to be on the wane. However, the recent development of vitri-
ﬁcation techniques has provided a means to cryopreserve biopsied
oocytes and embryos without a signiﬁcant decline in survival rates,
removing the principal bar to the clinical application of CGH (Sher
et al., 2007, Fragouli et al., unpublished). This advance has resulted
in resurgence in cases of PGS employing CGH. New CGH strategies,
utilizing vitriﬁcation, are now being clinically applied for oocyte,
cleavage stage and blastocyst screening on a large scale. Our most
recent blastocyst screening data are suggestive of a remarkable
improvement in embryo implantation and pregnancy rates (Wells
et al., 2008; Schoolcraft, Fragouli et al., 2008b). In a prospective
trial, involving patients of mean maternal age 37.5, with at least one
previous failed IVF attempt (mean 1.8), the proportion of CGH
cycles resulting in a live birth was 80%. This compared with 60%
for patients without aneuploidy screening. The probability of an indi-
vidual transferred embryo forming a pregnancy was 66.7% for the
CGH group compared with 27.9% without screening (P ¼ 0.00027).
These data suggest that the technical difﬁculties affecting earlier
chromosomescreening methodsare successfully overcome usingblas-
tocyst CGH, allowing preimplantation aneuploidy screening to ﬁnally
achieve the clinical potential predicted by theory. The highly signiﬁ-
cant improvement in the probability of a transferred embryo
forming a pregnancy indicates that comprehensive chromosomal
screening will be extremely useful in supporting efforts to maintain
high pregnancy rates while reducing the number of embryos trans-
ferred per cycle.
Although the use of vitriﬁcation has removed the most signiﬁcant
obstacle to the clinical application of CGH, the complexity of the
method remains a challenge for the laboratory responsible for the
genetic analysis. The CGH technique requires expertise in both mol-
ecular genetic and cytogenetic methods that are not generally avail-
able to fertility clinics. Thus, widespread clinical application is
dependent on the use of highly specialized reference centers. Further-
more, the need for cryopreservation may reduce the clinical options
available to patients and physicians. A more rapid technique, requiring
less molecular genetic and cytogenetic know-how, could be
advantageous.
Comparative genomic hybridization
using microarrays
Currently, the best hope for a simpliﬁed, rapid method of comprehen-
sive chromosomal screening is the microarray. As with conventional
CGH, most microarray methods involve the competitive hybridization
of differentially labeled test and reference DNA samples. However, in
this case, the labeled DNAs are hybridized to DNA probes afﬁxed to a
microscope slide rather than metaphase chromosomes. Each probe is
speciﬁc to a different chromosomal region and occupies a discrete
spot on the slide. Chromosomal loss or gain is revealed by the color
adopted by each spot after hybridization (i.e. ratio of ﬂuorescence
intensity for the two colors). Microarrays have an advantage over con-
ventional CGH in that the evaluation of ﬂuorescence ratios is simple
and easily automated and that the time required for hybridization is
generally less.
Microarray CGH has been successfully applied for the detection of
aneuploidies in single cells after whole genome ampliﬁcation (WGA)
using DOP-PCR or an alternative method known as multiple displace-
ment ampliﬁcation (MDA) (Hu et al., 2004; Wells et al., 2004; Le
Caignec et al., 2006). These approaches have permitted comprehen-
sive chromosome analysis to be achieved in ,48 h, within the time-
frame necessary for oocyte or cleavage stage embryo screening
without cryopreservation. It is very likely that microarray methods
can be further accelerated, possibly allowing screening of embryos
at even later stages (i.e. blastocysts), when the window available for
analysis is even narrower. In preliminary experiments, we have
managed to obtain array-CGH results within 10 h of receiving
samples. However, further research is needed to establish whether
accuracy rates are maintained at acceptable levels when hybridization
times are reduced.
Microarray CGH using bacterial artiﬁcial
chromosome probes
There are a variety of alternative microarray-CGH platforms available
for chromosomal screening and several different methods of WGA
that could be used in conjunction with them. Some researchers have
focused on the use of bacterial artiﬁcial chromosome (BAC) arrays,
consisting of thousands of spots, each of which comprises DNA frag-
ments covering relatively large fragments of chromosome (typically in
the region of 150–200 kb). Most, BAC-arrays contain a few thousand
individual probes (BAC clones), fewer than some alternative microar-
ray platforms, but more than enough for the principal objective of pre-
implantation embryo screening: the detection of losses and gains
affecting entire chromosomes.
The sizes of the probes are sufﬁciently large that each spot on the
slide hybridizes many ampliﬁed DNA fragments derived from the
region encompassed by the BAC. This is analogous to conventional
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anneal to all chromosomal regions. The annealing of multiple distinct
DNA fragments, derived from the same region of the chromosome,
reduces the inﬂuence of technical artifacts caused by preferential
ampliﬁcation and allele dropout (ADO). These problems frequently
affect the ampliﬁcation of individual DNA fragments in single cells
and could produce false losses and gains of chromosomal material.
However, in the case of BAC probes, each spot on the microarray pro-
vides an average result for the hundreds or thousands of ampliﬁed
fragments annealed to it, diluting the effect of individual fragments
with anomalous ampliﬁcation.
The main drawbacks of BAC arrays are on the manufacturing side,
where the nature of the probes and the way BAC arrays are fabricated
can lead to batch-to-batch variation in performance and problems with
reproducibility. For this reason, the manufacture of BAC arrays is best
left to expert laboratories specializing in this technology. We have
observed that some BAC clones do not perform reliably when used
in conjunction with ampliﬁed material, highlighting the need for
extensive validation experiments in order to identify and eliminate
poorly performing probes. However, even after problematic BACs
have been removed from the microarray, not all probes are expected
to give accurate results in every experiment. Given the nature of
WGA from a single cell, some random ﬂuctuations in the test and
reference ﬂuorescence ratios are expected. For this reason, diagnoses
cannot be based on the result from a single BAC, but must depend on
an average ﬂuorescence ratio obtained by pooling the data from
several neighboring probes. The need to combine results limits the
potential resolution of BAC arrays applied to single cells and increases
the number of probes needed to obtain an accurate result from each
chromosome.
Over the last few years, a variety of single cells, including polar
bodies and blastomeres, have been successfully screened using BAC
arrays (Wells et al., 2004; Stuerwald et al., 2007; Sanchez-Garcia
et al., unpublished). It appears that most forms of WGA are compati-
ble with this type of platform, although some caution should be exer-
cised when utilizing DOP-PCR, as this method is also often used to
enrich the DNA from the BAC clones as part of the microarray fabri-
cation process. A commercially available array for screening human
oocytes and embryos is now in the ﬁnal stages of preclinical testing,
with release expected toward the end of 2008 (Reprogenetics, unpub-
lished data).
Microarray CGH using chromosome libraries
Another type of microarray, which has yielded aneuploidy data from
single cells, utilizes chromosome-speciﬁc DNA libraries as probes.
DNA samples derived from individual chromosomes can be obtained
by microdissection (i.e. the removal of chromosomal material from a
slide using micromanipulation techniques) or in some cases by ﬂow
sorting. The samples of chromosomal DNA are ampliﬁed using
DOP-PCR and the repetitive sequences eliminated by negative sub-
traction hybridization with Cot-1 DNA and, for some chromosomes,
centromere-speciﬁc repeat sequences. Following another round of
ampliﬁcation, DNA from each of the chromosome-speciﬁc libraries
can be spotted onto the microarray (Hu et al., 2004).
This approach is promising for single cell analysis, as each spot on
the microarray is composed of an extremely heterogeneous mixture of
DNA fragments, derived from many sites along the length of each
chromosome. As with BAC probes, the inﬂuence of DNA fragments
affected by uneven ampliﬁcation is likely to be averaged out and
their negative effect on the data eliminated. The fact that each
chromosome-speciﬁc probe is depleted of repetitive sequences
should also improve the reliability of the diagnosis. Hybridization of
repetitive DNA elements is a problem for both microarray-based
and conventional CGH techniques, as some repeats are not entirely
blocked by competitive in situ suppression with Cot-1 DNA. The
number of repetitive elements on individual chromosomes can vary
from patient to patient, producing spurious changes in the test:refer-
ence ﬂuorescence ratio. This sometimes leads to difﬁculties enumerat-
ing speciﬁc chromosomes, particularly 19 and 22. With less repeat
sequences in the probes, this microarray platform should be less sus-
ceptible to such problems.
Microarrays utilizing chromosome libraries are likely to be less
expensive than alternative microarray platforms and may also turn
out to be more diagnostically robust. However, there is one drawback,
speciﬁcally a lack of resolution. While a chromosome library
approach is sufﬁcient for detecting aneuploidy affecting entire
chromosomes, it will struggle to detect losses and gains involving
smaller chromosome regions. De novo abnormalities of chromosome
structure have been detected in 8% of human embryos (Fragouli
et al., 2008). Although the clinical signiﬁcance of these anomalies
remains to be conﬁrmed, they are generally considered to be a nega-
tive indicator of embryo viability and thus their detection is desirable.
An inability to detect loss/gain of smaller chromosomal regions will
also preclude application of this strategy to patients carrying recipro-
cal translocations (a structural chromosome rearrangement character-
ized by an exchange of material between two chromosome arms).
Such patients produce a high proportion of embryos with aneuploidy
affecting the chromosomal fragments involved and are frequently
referred for PGD.
Microarray CGH using oligonucleotide probes
A third variety of microarray platform utilizes oligonucleotides, which
are synthesized in situ, directly on the surface of the solid support (i.e.
the slide) that forms the base for the microarray. The manufacturing
processes employed allow the production of high-density arrays
with very consistent probe performance. Depending on the manufac-
turer, the probes typically vary from 25 to 85 nucleotides in length.
One of the most promising oligonucleotide arrays is that offered by
Agilent, utilizing probes 60 nucleotides in length. CGH analyses per-
formed using Agilent arrays have successfully detected aneuploidy in
single cells isolated from chromosomally abnormal cell lines, as well
as in blastomeres derived from human embryos (Le Caignec et al.,
2006). More recently, Agilent arrays have been used clinically, for
the purpose of PGS, resulting in several pregnancies (Hellani et al.,
2008). This represents the ﬁrst successful clinical application of
microarray technology to the detection of aneuploid embryos and con-
ﬁrms that array-CGH can permit rapid, comprehensive chromosome
screening, without the need to cryopreserve embryos. The only draw-
back of using oligonucleotide arrays is that the small size of individual
probes increases the risk that artifactual losses and gains will be seen,
caused by errors introduced during WGA. It is possible to compensate
for this problem by analyzing large numbers of probes, but this may
increase the cost of the microarrays. Our data and that of others
suggest that the Agilent perform is compatible with single cell
array-CGH used in conjunction with several WGA techniques, includ-
ing MDA and the Genomeplex method commercialized by Sigma (Le
Caignec et al., 2006; Hellani et al., 2008; Alfarawati and Wells,
unpublished).
Single nucleotide polymorphism microarrays
Another form of oligonucleotide array, capable of detecting aneu-
ploidy, is based upon the analysis of single nucleotide polymorphisms
(SNPs). SNPs are common polymorphic DNA sequences found
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707throughout the genome. Most SNP-microarrays interrogate between
10 000 and 500 000 individual SNPs, located at numerous positions
along the length of each chromosome. Although all of the microarray
platforms discussed previously utilize an approach similar to conven-
tional CGH, involving simultaneous hybridization of differen-
tially labeled test and reference DNAs to the same microarray,
SNP-microarrays employ a somewhat different strategy. Rather than
being combined with the normal reference DNA, the ampliﬁed
material from the test sample is hybridized separately, with reference
DNA samples assessed in parallel. As test and reference DNAs hybri-
dize to separate areas of the slide, both can be labelled with the same
ﬂuorochrome. Chromosomal copy number is calculated in two ways.
Firstly, the alleles detected at each SNP locus are compared with those
of the parents, revealing which parental chromosomes were inherited
by the embryo. The inheritance of three distinct chromosomal haplo-
types indicates the presence of a trisomic chromosome, while mono-
somies are revealed by homozygosity for all loci on the affected
chromosome. Secondly, ﬂuorescence intensities obtained for test
and reference hybridizations are compared. If probes from a given
chromosome display brighter signals for the test DNA than the refer-
ence DNA, an excess of chromosomal material (e.g. trisomy) is
predicted. Conversely, reduced ﬂuorescence for the test sample is
associated with chromosome loss. Preliminary data suggests that
aneuploidy screening using this strategy is accurate, although some
questions remain concerning the reliability of trisomy detection. Not
all trisomies are caused by the presence of three genetically distinct
copies of the same chromosome (i.e. in some instances two of the
three copies are identical). In such cases, detection by SNP-array is
solely dependent on changes in ﬂuorescence intensity. More data is
required to determine the true accuracy of trisomy detection using
SNP-arrays in a clinical scenario.
A signiﬁcant advantage of SNP-microarrays is that the probes used
provide genotype data in addition to chromosome copy number infor-
mation. The simultaneous analysis of thousands of polymorphisms
scattered throughout the genome produces a unique DNA ﬁngerprint
for each embryo tested. The DNA ﬁngerprint allows parental origin
to be conﬁrmed, reducing the risk that a laboratory error could lead
to embryos being transferred to the wrong patient. A further beneﬁt
of embryo ﬁngerprinting is that any children born following the pro-
cedure can be tested and their ﬁngerprints matched with those of the
embryos transferred. This allows the embryo(s) that successfully pro-
duced children to be traced, providing an extremely powerful tool for
research studies aimed at identifying factors that affect embryo
implantation potential.
One of the most widely used SNP-microarrays is produced by Affy-
metrix. This platform employs short probes, 25 nucleotides in length,
which are synthesized on the surface of the array using photolitho-
graphic techniques. A software package (CNAT, Affymetrix) calcu-
lates chromosomal copy number based on ﬂuorescence intensity of
probes mapping to each chromosome. An alternative platform is
that offered by Illumina. Rather than directly afﬁxing SNP-speciﬁc
probes to a slide, or synthesizing oligonucletides in situ, the Illumina
strategy involves coating 3 mm silica beads with hundreds of thou-
sands of copies of an oligonucleotide probe. The beads are held in
microwells on either of two substrates: ﬁber optic bundles or silica
slides. As with Affymetrix microarrays, aneuploidy can be detected
by analyzingthe signalintensity for probesderived fromeach chromo-
some. Additionally, both platforms generate DNA ﬁngerprints, allow-
ing embryo identiﬁcation.
At the time of writing, no clinical cases of PGD or PGS utilizing
SNP-microarrays have been reported in the literature. However,
encouraging data from preclinical studies has begun to emerge. The
Affymetrix 250K platform, an array comprising 250 000 different
SNPs dispersed across all chromosomes, has been employed for the
analysis of single blastomeres, successfully detecting several aneu-
ploid chromosomal conﬁgurations in non-transferred embryos (Treff
et al., 2007). Additionally, Scott et al. have presented interesting
data from a prospective ‘non-selection’ trial using the same platform
(Scott et al., 2008). In that study, cells were biopsied from preimplan-
tation embryos and assessed using SNP microarrays, providing a
reliable DNA ﬁngerprint and revealing the presence of aneuploidy.
Unfortunately, the chromosome screening results were not available
until after transfer to the uterus had taken place and could not therefore
be used to assist embryo selection. Upon analysis of the microarray
data, it was later discovered that some of the embryos transferred
had been aneuploid. Fetal DNA was obtained from any pregnancies
that resulted and a DNA ﬁngerprint produced, allowing the embryos
that formed pregnancies to be identiﬁed. Remarkably, the negative
predictive value of aneuploidy screening was found to be 100% (0/31
embryos with aneuploidy detected in the biopsied cell formed an
ongoing pregnancy, 26 failing to implant and 5 miscarrying). The
positive predictive value was also encouraging, 42.9% of embryos
diagnosednormal formedanongoingpregnancy.The factthat positive
predictive value fell short of 100% emphasizes that, while extremely
important, aneuploidy is not the only problem impacting embryo via-
bility and pregnancy.
As well as the promising data obtained using Affymetrix micro-
arrays, Illumina SNP-microarrays have also yielded encouraging
results. Analysis of 370 000 SNPs scattered throughout the
genome has permitted accurate detection of chromosomal losses and
gains in single cells derived from cytogenetically characterized
aneuploid cell lines and blastomeres derived from human embryos
(Kearns et al., 2008; Rabinowitz et al., 2008). Furthermore, analysis
of DNA samples from the mother and father, in addition to DNA
from the embryo, has made it possible to follow the inheritance of
each parental chromosome. Not only does this provide interesting
scientiﬁc information, such as revealing the parental origin of extra
chromosomesin trisomic embryos, but it also yields data on the inheri-
tance of speciﬁc genetic loci, including those associated with disease
(Kearns et al., 2008).
In general, disease causing mutations are not detected directly using
SNP-microarrays (although this is technically possible in some cases).
Rather they are detected indirectly via a linkage approach. This
involves the genotyping of SNPs located in close proximity to the
mutation site, on the same chromosome (i.e. linked polymorphisms).
It is usually possible to identify speciﬁc alleles, which do not cause
the disease, but are always inherited along with it and can therefore
be used to infer a diagnosis. Proof of principle studies has shown
that accurate data concerning the inheritance of disease-associated
polymorphisms can be obtained from single cells using SNP-microarrays
(Handyside et al., 2008). This potentially opens up the possibility of
using SNP-microarray platforms for the concomitant detection of
chromosome anomalies and single gene disorders. Traditionally, the
simultaneous diagnosis of aneuploidy and gene mutations has been
problematic for PGD, as the FISH techniques used for chromosome
screening and the PCR methods employed for single gene testing
are incompatible. A limited chromosome screen is possible using
PCR, but such protocols fail to screen most of the chromosomes and
have a limited ability to detect errors arising in meiosis II or after
fertilization.
The only drawbacks of analysis using SNP-microarrays are a lack of
diagnostic accuracy at individual SNP loci and the high expense of the
microarrays and labeling techniques. The WGA methods, required to
generate sufﬁcient DNA from a single cell for subsequent microarray
analysis, exacerbate problems such as ADO and preferential ampliﬁ-
cation. This causes many of the SNP loci to be incorrectly genotyped.
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mosomal haplotypes can still be constructed, and the inheritance of
chromosomal regions containing mutations deduced, despite the pre-
sence of many errors. However, statistical processing of the data is
necessary in order to identify correctly genotyped SNPs from those
giving unreliable results and extract meaningful data (Handyside
et al., 2008; Rabinowitz et al., 2008). Inevitably, the elimination of
large numbers of incorrectly genotyped loci from the data set has
the effect of reducing the resolution of the microarray and prevents
reliable diagnosis based upon direct analysis of individual mutations.
Currently, SNP arrays represent an expensive option for oocyte/
embryo screening. With commercial subsidy, it is possible to offer
this method of screening to a limited population of patients.
However, it is not yet clear whether this platform can be adapted to
create an inexpensive, widely applicable test. Additionally, many of
the existing software interfaces will need modiﬁcation prior to exten-
sive clinical application, in order to make analysis less laborious and
time-consuming.
Summary
Accurate methods for the simultaneous analysis of all 24 types of
chromosome (22 autosomes, X and Y) look set to usher in a new
era of embryo evaluation. Recent data clearly indicate that compre-
hensive chromosomal screening assists the identiﬁcation of viable
embryos for transfer to the uterus, leading to improved IVF outcomes
(Schoolcraft et al., 2008a). The dramatic improvement in implantation
rate is particularly noteworthy and will be an extremely useful tool for
maintaining high pregnancy rates while reducing the number of
embryos transferred each cycle. The introduction of highly reliable
vitriﬁcation techniques for embryo cryopreservation has removed
the last remaining obstacle to the widespread application of conven-
tional CGH and the number of clinical cases utilizing this screening
method is expanding rapidly. Microarray methods of chromosome
screening also continue to show technical improvement. Platforms uti-
lizing BACs, chromosome-speciﬁc libraries, oligonucleotides and
SNPs have all succeeded in detecting aneuploidies in single blasto-
meres and are now being clinically applied. It remains to be seen
which microarray approach will ultimately provide the optimal com-
bination of accuracy, speed and cost, but given the rapid evolution
of these technologies a cost-effective and reliable test seems close at
hand. For the time being, however, conventional CGH remains the
test of choice for comprehensive aneuploidy screening.
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